Results 151 to 160 of about 36,274 (199)
A non‐canonical core transcriptional regulatory circuit, composed of ID3, SMAD3, and NR2F2, drives Osimertinib resistance in non‐small cell lung cancer through super‐enhancer‐mediated activation of EPAS1, which couples neuroendocrine differentiation with ferroptosis evasion.
Aochu Liu +15 more
wiley +1 more source
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer. [PDF]
Li C +27 more
europepmc +1 more source
This research innovatively illustrates baicalin’s multifaceted mechanisms in enhancing piglets’ intestinal health: modulating bile acid metabolism via probiotics, reinforcing tight junction proteins (ZO‐1/claudin), suppressing TLR4/NF‐κB‐mediated inflammation, whereas promoting growth and reducing diarrhea.
Yuhui Gao +6 more
wiley +1 more source
Novel therapeutic strategies for metastatic castration‑resistant prostate cancer: Beyond androgen receptor pathway inhibition (Review). [PDF]
Wang Y, Xie Y, Zhao Q.
europepmc +1 more source
Applications of Artificial Intelligence in Cancer Diagnosis and Treatment
This review explores how AI and multimodal data fusion transform oncology through enhanced screening, precision diagnosis, and personalized therapy. By dissecting core challenges—including data bias and explainability—it provides a strategic framework for the digital transformation and ethical implementation of AI in clinical cancer care.
Yifeng Xie +6 more
wiley +1 more source
Circulating Tumor DNA Genomic Profiling in <sup>223</sup>Ra-Treated Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study. [PDF]
Shiota M +17 more
europepmc +1 more source
The Local Effects of Systemic Therapies in Urological Oncology: A Systematic Review
ABSTRACT Background Systemic therapies can impact local disease progression in genitourinary malignancies, potentially reducing the necessity for extensive surgery. Understanding these effects is crucial for optimizing treatment approaches in urologic oncology.
Sharon Nordheimer, Ofer N. Gofrit
wiley +1 more source
Bipolar androgen therapy as platform for personalized medicine in castration-resistant prostate cancer. [PDF]
Lilleby W, Geinitz H, Denmeade S.
europepmc +1 more source
Abstract Background Vobramitamab duocarmazine is an investigational antibody–drug conjugate (ADC) targeting B7 homolog 3 (B7‐H3) with a cytotoxic duocarmycin‐based DNA‐alkylating payload. This study evaluated its safety and antitumor activity in advanced solid tumors.
Eugene Shenderov +20 more
wiley +1 more source

